Compare IOL Chemicals with Similar Stocks
Dashboard
Poor long term growth as Net Sales has grown by an annual rate of 0.38% and Operating profit at 7.22% over the last 5 years
With ROE of 6.6, it has a Very Expensive valuation with a 1.2 Price to Book Value
Despite the size of the company, domestic mutual funds hold only 0.04% of the company
Stock DNA
Pharmaceuticals & Biotechnology
INR 2,179 Cr (Small Cap)
18.00
37
1.37%
-0.01
6.62%
1.22
Total Returns (Price + Dividend) 
Latest dividend: 1 per share ex-dividend date: Feb-17-2026
Risk Adjusted Returns v/s 
Returns Beta
News

IOL Chemicals & Pharmaceuticals Ltd is Rated Sell
IOL Chemicals & Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
IOL Chemicals & Pharmaceuticals Ltd: Valuation Shift Signals Price Attractiveness Decline
IOL Chemicals & Pharmaceuticals Ltd has seen a marked shift in its valuation parameters, moving from fair to very expensive territory, prompting a downgrade in its investment grade. Despite a recent surge in share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now exceed historical and peer averages, raising questions about its price attractiveness amid sector volatility.
Read full news article
IOL Chemicals & Pharmaceuticals Ltd Hits Intraday High with 7.02% Surge
IOL Chemicals & Pharmaceuticals Ltd recorded a robust intraday performance on 18 Mar 2026, surging 7.02% to touch a day’s high of Rs 72.99. This marks a notable rebound after five consecutive days of decline, significantly outperforming the Pharmaceuticals & Biotechnology sector and the broader Sensex index.
Read full news article Announcements 
Disclosure Under SEBI (Prohibition Of Insider Trading Regulation) 2015
19-Mar-2026 | Source : BSEDisclosure under SEBI (PIT) Regulations
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
19-Mar-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Mayadevi Polycot Ltd & PACs
Disclosure Under SEBI (Prohibition Of Insider Trading Regulation) 2015
19-Mar-2026 | Source : BSEDisclosure under SEBI (PIT) Regulations
Corporate Actions 
No Upcoming Board Meetings
IOL Chemicals & Pharmaceuticals Ltd has declared 50% dividend, ex-date: 17 Feb 26
IOL Chemicals & Pharmaceuticals Ltd has announced 2:10 stock split, ex-date: 11 Mar 25
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 6 Schemes (0.02%)
Held by 59 FIIs (2.08%)
Maya Devi Polycot Limited (21.54%)
Vasudeva Commercials Limited (4%)
30.51%
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
QoQ Growth in quarter ended Dec 2025 is 2.27% vs 2.87% in Sep 2025
QoQ Growth in quarter ended Dec 2025 is -31.33% vs -11.67% in Sep 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 8.86% vs -7.25% in Sep 2024
Growth in half year ended Sep 2025 is 30.09% vs -41.34% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 9.55% vs -4.75% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 21.29% vs -34.79% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is -2.51% vs -3.80% in Mar 2024
YoY Growth in year ended Mar 2025 is -24.82% vs -3.39% in Mar 2024






